Now live: European new issue coverage and historical data, for free. → Explore All Content & Delivery Channels
Log In
No results found for "".

Commentary & Deal Flow

LAUNCHED: Zimmer Biomet Holdings €500m 7yr Sr Unsec; MS+107bp

IGC European Market: Deal Flow - General

Issuer

Term

Maturity

Size

Ranking

Type

IPT

Spread Set

Zimmer Biomet Holdings

7yr

12-Nov-33

€500m

Sr Unsec

Fixed

MS+135/140

MS+107


Launched: 7yr: €500m @ MS+107bp
IPTs: 7yr: MS+135/140bp


  • Active Bookrunners: Barclays (B&D), Citigroup, HSBC, Morgan Stanley, RBC Capital Markets
  • Issuer: Zimmer Biomet Holdings, Inc.
  • Issuer LEI: 2P2YLDVPES3BXQ1FRB91
  • Issuer Ratings: Baa2 (Stable) by Moody's / BBB (Stable) by S&P / BBB (Stable) by Fitch
  • Expected Issue Ratings: Baa2 (Stable) by Moody's / BBB (Stable) by S&P / BBB (Stable) by Fitch
  • Format: SEC Registered, Senior, Unsecured
  • Settlement: 12-Nov-26 (T+5 clearing system business days)
  • Maturity: 12-Nov-33
  • Tranche: 7yr
  • Size: €500m
  • Coupon: Fixed, Ann, Act/Act (ICMA)
  • Optional Redemption: 3-month par call / MWC / Tax Call
  • B&D: Barclays
  • ISIN: XS3559427243
  • CUSIP: 98956P BE1
  • Common Code: 355942724
  • Docs: SEC Registered, NYSE Listing, New York Law
  • Clearing: Clearstream Banking S.A. ("Clearstream") and Euroclear Bank SA/NV ("Euroclear")
  • Denominations: €100k and integral multiples of €1k in excess thereof
  • Selling Restrictions: As per Preliminary Prospectus Supplement. Sales to Canada via exemption.
  • UoP: General corporate purposes, which may include the repayment of other indebtedness (which could include a portion of the Issuer's 2.425% notes due 2026 and/or a portion of the Issuer's 4.700% notes due 2027), share repurchases, financing capital commitments and financing acquisitions. The Issuer may, including in the near term, also pursue one or more additional debt capital markets transactions, the proceeds of which may be used for general corporate purposes, which may include the repayment of a portion of the Issuer's 2.425% notes due 2026 and/or a portion of the Issuer's 4.700% notes due 2027.
  • Stabilization: Relevant stabilization regulations including FCA/ICMA apply.
  • Target Market: MiFID II and UK MiFIR - professionals/ECPs-only / No EEA PRIIPs key information document (KID) or UK disclosure document required by DISC - Manufacturer target market (MiFID II and UK MiFIR product governance) is eligible counterparties and professional clients only (all distribution channels). No EEA PRIIPs KID or UK DISC disclosure document has been prepared as the notes are not available to retail investors in the European Economic Area or the UK.
  • Timing: Books open, Today's business
  • Books Subject: 12.40 UKT
  • Allocations: To follow - Barclays B&D
We use functional cookies to make this site work properly and marketing cookies to personalize content. By continuing or clicking "Ok", you consent to our use of cookies. See our Cookie Policy for more information.
By continuing, you agree to FINSIGHT's Terms of Use and Privacy Policy.